Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers

Journal of Crohn's and Colitis

Volumn 5, Issue 4, 2011, Pages 301-316

  Buchanan, James ^a   Wordsworth, Sarah ^a   Ahmad, Tariq ^b   Perrin, Angela ^c   Vermeire, Severine ^d   Sans, Miquel ^e   Taylor, Jenny ^f   Jewell, Derek ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Costs; Crohn's disease; Health economics; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BARIUM; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISOLONE;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BARIUM MEAL; CLINICAL NURSE SPECIALIST; COLONOSCOPY; COLORECTAL SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COST OF ILLNESS; CROHN DISEASE; DRUG COST; FECES ANALYSIS; FECES CULTURE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REMISSION; SIGMOIDOSCOPY; STOMA; SURGEON; ULCERATIVE COLITIS; UNITED KINGDOM; WESTERN EUROPE;

ADULT; EUROPE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MODELS, ECONOMIC;

EID: 79958801012     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.02.005     Document Type: Article

References (73)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126(6):1504-1517.
2. Williams J.G., Roberts S.E., Ali M.F., Cheung W.Y., Cohen D.R., Demery G., Edwards A., Greer M., Hellier M.D., Hutchings H.A., Ip B., Longo M.F., Russell I.T., Snooks H.A., Williams J.C. Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut February 1, 2007, 56:1-113.
3. Feagan B.G. Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999, 13(s4):29-37.
4. Kappelman M.D., Rifas-Shiman S.L., Porter C.Q., Ollendorf D.A., Sandler R.S., Galanko J.A., Finkelstein J.A. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008 Dec, 135(6):1907-1913.
5. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008, 14(43):6641-6647.
6. Arseneau K.O., Cohn S.M., Cominelli F., Connors Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001, 120(7):1640-1656.
7. Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005, 23(9):875-888.
8. Cohen R.D. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis 2008, 14(12):1707-1714.
9. Dryden G.W. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther 2009 Aug, 9(8):967-974.
10. Reenaers C., Louis E., Belaiche J. Review: current directions of biologic therapies in inflammatory bowel disease. Ther Adv Gastroenterol March 1, 2010, 3:99-106.
11. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., Bloomfield R., Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 Jul 19, 357(3):228-238.
12. Bassi A., Dodd S., Williamson P., Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53(10):1471-1478.
13. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002, 20:639-652.
14. Cohen R.D., Yu A.P., Wu E.Q., Xie J., Mulani P.M., Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010, 31(7):693-707.
15. Hay J., Hay A. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992, 14(4):309-317.
16. Feagan B.G., Vreeland M.G., Larson L.R., Bala M.V. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol Aug 2000, 95(8):1955-1960.
17. Odes S., Vardi H., Friger M., Wolters F., Russel M.G., Riis L., Munkholm P., Politi P., Tsianos E., Clofent J. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006, 131(3):719-728.
18. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., De Vos M., van Deventer S., Stitt L., Donner A., Vermeire S., Van De Mierop F.J., Coche J.-C.R., van der Woude J., Ochsenkühn T., van Bodegraven A.A., Van Hootegem P.P., Lambrecht G.L., Mana F., Rutgeerts P., Feagan B.G., Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371(9613):660-667.
19. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 Apr, 13(4):397-409.
20. Mesterton J., Jönsson L., Almer S.H.C., Befrits R., Friis-Liby I., Lindgren S. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis 2009, 15(12):1882-1890.
21. Carter M.J., Lobo A.J., Travis S.P.L. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004, 53(suppl_5):v1-v16.
22. Travis S.P.L., Stange E.F., Lémann M., Øresland T., Bemelman W.A., Chowers Y., Colombel J.F., Haens G.D., Ghosh S., Marteau P., Kruis W., Mortensen N.J.M., Penninckx F., Gassull M. European evidence-based consensus on the management of ulcerative colitis. Curr Manage 2008, 2(1):24-62.
23. Dignass A., Assche G.V., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., Danese S., Hoore A.D., Gassull M., Gomollón F., Hommes D.W., Michetti P., Morain C.O., Öresland T., Windsor A., Stange E.F., Travis S.P.L. The second European evidence-based consensus on the diagnosis and management of Crohn's disease. Curr Manage 2010, 4(1):28-62.
24. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011 Jan, 17(1):471-478.
25. Office for National Statistics United Kingdom interim life tables 2009.
26. Drummond M., Sculpher M., Torrance G., O'Brien B., Stoddart G. Methods for the economic evaluation of health care programmes 2005, Oxford University Press.
27. HM Treasury Green book, appraisal and evaluation in central government 2006.
28. HM Revenue and Customs Foreign exchange rates and spot rates (09/02/2010): Available from:. http://www.hmrc.gov.uk/exrate/index.htm.
29. Langholz E., Munkholm P., Davidsen M., Nielsen O.H., Binder V. Changes in extent of ulcerative colitis a study on the course and prognostic factors. Scand J Gastroenterol 1996, 31(3):260-266.
30. Rubin G.P., Hungin A.P.S., Kelly P.J., Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000, 14(12):1553-1559.
31. Office for National Statistics Population estimates for UK, England and Wales, Scotland and Northern Ireland [28/08/09]; Available from:. http://www.statistics.gov.uk/statbase/product.asp?vlnk=15106.
32. EUROSTAT Data explorer Accessed 19/12/2010 at. http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/.
33. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 May, 17(5):479-500.
34. Briggs A. Handling uncertainty in economic evaluation. Economic evaluation in health care: merging theory with practice 2001, 286. Oxford University Press, Oxford. M.F. Drummond, A. McGuire (Eds.).
35. Silverstein M.D. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117(1):49-57.
36. Wolters F.L., Russel M.G., Sijbrandij J., Schouten L.J., Odes S., Riis L., Munkholm P., Langholz E., Bodini P., O'Morain C., Katsanos K., Tsianos E., Vermeire S., Van Zeijl G., Limonard C., Hoie O., Vatn M., Moum B., Stockbrugger R.W. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl May 2006, 243:46-54. The European Collaborative Study Group On Inflammatory Bowel D.
37. Lofland J., Naim A., Rizzo J.A., Gunnarsson C.L., Chen J., Waters H.C. M1033 The direct costs of inflammatory bowel disease: evidence from United States National Survey data. Gastroenterology 2010, 138(5):S-317.
38. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., Loftus E.V., Lomax K.G., Yu A.P., Wu E.Q., Chao J., Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008 Nov, 135(5):1493-1499.
39. Lichtenstein G.R., Yan S., Bala M., Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 Jan, 99(1):91-96.
40. Horjus C., Groenen M., den Hartog G., Thies J., Bilgen E., Wahab P. T1309 Time trends in the use of medication and intestinal surgery in a Dutch cohort of patients with Crohn's disease (1980-2004). Gastroenterology 2010, 138(5):S-534.
41. Gupta R., Sheikh A., Strachan D.P., Anderson H.R. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy 2004 Apr, 34(4):520-526.
42. Asthma U.K. Living on a knife edge 2004.
43. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002 Jul, 45(7):S5-S12.
44. Turnbull G.K., Vallis T.M. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol 1995 Sep, 90(9):1450-1454.
45. Wordsworth S., Buchanan J., Regan R., Davison V., Smith K., Dyer S., Campbell C., Blair E., Maher E., Taylor J., Knight S. Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. Genomics Med 2007, 1(1):35-45. 10.1007/s11568-007-9005-6.
46. Sjoqvist U., Lofberg R. Is mesalazine useful in Crohn's disease?. Challenges in inflammatory bowel disease 2006, 281-292. Blackwell Publishing Limited, Oxford. D. Jewell, N. Mortensen, A. Steinhart, J. Pemberton, B. Warren (Eds.).
47. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. Gut 1963 Dec, 4:299-315.
48. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006 Jul 15, 24(2):319-330.
49. Truelove S.C., Watkinson G., Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962 Dec 29, 2(5321):1708-1711.
50. Travis S. Refractory distal colitis. Challenges in inflammatory bowel disease 2006, 124-143. Blackwell Publishing Limited, Oxford. D.P. Jewell, N.J. Mortensen, A.H. Steinhart, J.H. Permberton, B.F. Warren (Eds.).
51. Bouhnik Y., Scemama G., Taï R., Matuchansky C., Rambaud J.C., Lémann M., Modigliani R., Mary J.Y. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347(8996):215-219.
52. Lewis J.D., Schwartz J.S., Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118(6):1018-1024.
53. Probert C.S.J., Hearing S.D., Schreiber S., K++hbacher T., Ghosh S., Arnott I.D.R., Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52(7):998-1002.
54. Steinhart A. Is mesalazine useful in Crohn's disease?. Challenges in inflammatory bowel disease 2006, 181-193. Blackwell Publishing Limited, Oxford. D.P. Jewell, N.J. Mortensen, A.H. Steinhart, J.H. Permberton, B.F. Warren (Eds.).
55. Summers R.W., Switz D.M., Sessions J.T., Becktel J.M., Best W.R., Kern F., Singleton J.W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979 Oct, 77(4 Pt 2):847-869.
56. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 Feb, 86(2):249-266.
57. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Gillies R., Hopkins M., Hanauer S.B., McDonald J.W.D. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995, 332(5):292-297. The North American Crohn's Study G.
58. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med Jul 15 1995, 123(2):132-142.
59. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Koval J., Wong C.J., Hopkins M., Hanauer S.B., McDonald J.W. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med Jun 1 2000, 342(22):1627-1632.
60. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
61. Mannon P. GAIN for loss: adalimumab for infliximab - refractory Crohn disease. Ann Intern Med 2007, 146(12):888-890.
62. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. The Crohn's Dc. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337(15):1029-1036.
63. Joint Formulary Committee British national formulary 2008, British Medical Association and Royal Pharmaceutical Society of Great Britain, London. 55 ed.
64. Cohen R.D. Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results?. Gastroenterology 2006 Feb, 130(2):607-608.
65. Department of Health NHS reference costs 2007-2008 2008, Department of Health, London.
66. Jewell D.P., Satsangi J., Lobo A., Probert C., Forbes A., Ghosh S., Shaffer J., Frenz M., Drummond H., Troy G., Turner S., Younge L., Evans L., Moosa M., Rodgers-Gray B., Buchan S. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005, 17:1047-1052.
67. Department of Health NHS reference costs 2006-2007 2007, Department of Health, London.
68. Curtis L. Unit costs of health and social care 2008 2008, Personal Social Services Research Unit, University of Kent, Canterbury.
69. Department of Health Drug tariff: National Health Service, England and Wales April 2008 2008, Department of Health, London.
70. National Centre for Social Research, Department of Epidemiology at Royal Free, University College Medical School Health survey for England 2006 2008, Department of Health, London.
71. Ardizzone S., Bianchi Porro G. Perianal Crohn's disease: overview. Dig Liver Dis 2007, 39(10):957-958.
72. Domselaar M., Bermejo F., Román A., Garrido E., Algaba A., Die J. S1210 Long-term outcome of perianal Crohn's disease under normal clinical practice conditions. Gastroenterology 2010, 138(5):S-205.
73. Safar B., Sands D. Perianal Crohn's disease. Clin Colon Rectal Surg 2007 Nov, 20(4):282-293.